中华胸心血管外科杂志
中華胸心血管外科雜誌
중화흉심혈관외과잡지
Chinese Journal of Thoracic and Cardiovascular Surgery
2012年
11期
662-664
,共3页
葛晓晓%澹台冀澂%刘友如%赵珩%姜丽岩
葛曉曉%澹檯冀澂%劉友如%趙珩%薑麗巖
갈효효%담태기징%류우여%조형%강려암
癌,非小细胞肺%免疫组织化学%甲状腺转录因子-1%预后
癌,非小細胞肺%免疫組織化學%甲狀腺轉錄因子-1%預後
암,비소세포폐%면역조직화학%갑상선전록인자-1%예후
Carcinoma,non-small-cell lung%Immunohistochemistry%TTF-1%Prognosis
目的 探讨甲状腺转录因子-1(TTF-1)在Ⅰ期非小细胞肺癌(NSCLC)中的表达、临床意义及其预后价值.方法 利用免疫组织化学技术检测129例Ⅰ期NSCLC组织中TTF-1的表达,分析其与临床因素及预后的关系.结果 TTF-1在Ⅰ期NSCLC中阳性表达率为64.3％,其中在肺腺癌中的阳性率高于其他亚组(x2=25.231,P＜0.001),低年龄组(＜60岁)高于高年龄组(≥60岁)(x2=4.581,P=0.032)、女性组高于男性组(x2 =4.900,P=0.027)及肿瘤的分化程度较高组(中分化、高分化)高于较低分化组(x2＝11.519,P=0.019).TTF-1阳性组和阴性组的中位无病生存期(DFS)及总生存期(OS)分别为38.9个月对27.8个月(P =0.023)及64.10个月对50.68个月(P=0.013).Cox回归分析显示,TTF-1阳性表达(P =0.005),肿瘤分化程度(P=0.044)是Ⅰ期非小细胞肺癌的独立预后因素.结论 TTF-1阳性表达患者预后较好.TTF-1阳性表达、肿瘤分化程度为Ⅰ期NSCLC预后独立的影响因素.
目的 探討甲狀腺轉錄因子-1(TTF-1)在Ⅰ期非小細胞肺癌(NSCLC)中的錶達、臨床意義及其預後價值.方法 利用免疫組織化學技術檢測129例Ⅰ期NSCLC組織中TTF-1的錶達,分析其與臨床因素及預後的關繫.結果 TTF-1在Ⅰ期NSCLC中暘性錶達率為64.3％,其中在肺腺癌中的暘性率高于其他亞組(x2=25.231,P＜0.001),低年齡組(＜60歲)高于高年齡組(≥60歲)(x2=4.581,P=0.032)、女性組高于男性組(x2 =4.900,P=0.027)及腫瘤的分化程度較高組(中分化、高分化)高于較低分化組(x2＝11.519,P=0.019).TTF-1暘性組和陰性組的中位無病生存期(DFS)及總生存期(OS)分彆為38.9箇月對27.8箇月(P =0.023)及64.10箇月對50.68箇月(P=0.013).Cox迴歸分析顯示,TTF-1暘性錶達(P =0.005),腫瘤分化程度(P=0.044)是Ⅰ期非小細胞肺癌的獨立預後因素.結論 TTF-1暘性錶達患者預後較好.TTF-1暘性錶達、腫瘤分化程度為Ⅰ期NSCLC預後獨立的影響因素.
목적 탐토갑상선전록인자-1(TTF-1)재Ⅰ기비소세포폐암(NSCLC)중적표체、림상의의급기예후개치.방법 이용면역조직화학기술검측129례Ⅰ기NSCLC조직중TTF-1적표체,분석기여림상인소급예후적관계.결과 TTF-1재Ⅰ기NSCLC중양성표체솔위64.3％,기중재폐선암중적양성솔고우기타아조(x2=25.231,P＜0.001),저년령조(＜60세)고우고년령조(≥60세)(x2=4.581,P=0.032)、녀성조고우남성조(x2 =4.900,P=0.027)급종류적분화정도교고조(중분화、고분화)고우교저분화조(x2＝11.519,P=0.019).TTF-1양성조화음성조적중위무병생존기(DFS)급총생존기(OS)분별위38.9개월대27.8개월(P =0.023)급64.10개월대50.68개월(P=0.013).Cox회귀분석현시,TTF-1양성표체(P =0.005),종류분화정도(P=0.044)시Ⅰ기비소세포폐암적독립예후인소.결론 TTF-1양성표체환자예후교호.TTF-1양성표체、종류분화정도위Ⅰ기NSCLC예후독립적영향인소.
Objective To study the expression and clinical significance of thyroid transcription factor-1 (TTF-1) in stage Ⅰ non-small cell lung cancer (NSCLC) after operation and to 1 investigate the values in identification of the prognosis of stage Ⅰ NSCLC.Methods The expression of TTF-1 in 129 specimens of stage Ⅰ NSCLC was detected by immunohistochemistry.Results The positive rate of TTF-1 in stage Ⅰ NSCLC was 64.3％.There were significant differences in TTF-1 expression rate among pathological subtypes (x2 =25.231,P ＜ 0.001),different ages (x2 =4.581,P =0.032),sex (x2 =4.900,P =0.027) and differentiation degrees(x2 =11.519,P =0.019).Univariate analysis suggested that in the stage Ⅰ NSCLC patients,the median disease-free survival and overall survival of those positive for TTF-1 expression were superior to those negative:38.9 months versus 27.8 months (P =0.023) and 64.10 months versus 50.68months (P =0.013).Cox regression analysis suggested that TTF-1 expression,tumor differentiation degrees were independent factors affecting the prognosis of stage Ⅰ NSCLC.Conclusion Patients with TTF-1 positive expression often had better survival.Positive expression of TTF-1 and differentiation degree of tumor were independent prognostic factors to affect the prognosis of NSCLC.
